1 of 1
Story summary
- Sorfequiline demonstrated effectiveness in a multicountry trial of 309 participants, potentially improving cure rates and shortening TB treatment.
- The World Health Organization reported 10.7 million global TB cases last year, and 1.23 million deaths.
- Researchers say the treatment could streamline care by enabling immediate administration.
- Concerns exist about universal use, as it may deter investment in broader health innovations.
- TB Alliance plans to launch a phase-3 trial in 2026.
